Trial Profile

A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elebsiran (Primary) ; Peginterferon alfa (Primary) ; VBI 2601 (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Acronyms ENHANCE
Sponsors Brii Biosciences

23 May 2025 Planned number of patients changed from 180 to 250.
23 May 2025 Planned End Date changed from 1 May 2027 to 1 Jul 2027.
23 May 2025 Planned primary completion date changed from 1 May 2026 to 1 Jul 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com